Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

NCT07340398 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Early Breast Cancer

Interventions

DRUG: Nab paclitaxel
DRUG: Carboplatin
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: SHR-A1811
DRUG: Pyrotinib

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University